Kamada

Company Overview

Snapshot

Founded in December 1990 by David Tsur, Kamada operates with 201–500 employees. The company has raised $150M across 7 funding rounds from 2 investors. In May 2023, Kamada received an investment from FIMI Opportunity Funds.

Business overview

Kamada is a plasma-derived protein therapeutics company that leverages its proprietary platform technology to extract and purify proteins from human plasma. The company develops and commercializes a portfolio of products, including two FDA-approved therapies: GLASSIA for Alpha-1 Antitrypsin (AAT) deficiency and KEDRAB for rabies immune globulin. Kamada serves global markets within the healthcare and life sciences sectors, specifically targeting providers and pharmaceutical industries with its biopharmaceutical products.

Strategic signal

In October 2022, Kamada secured a $22 million extension for its Canadian supply tender, indicating continued demand and strategic importance of its plasma-derived products in key international markets. This extension reinforces the company's operational stability and its role as a reliable supplier in the biopharmaceutical industry, signaling sustained revenue streams and market penetration to investors.

Company Intelligence Q&A

What was a significant recent operational expansion for Kamada?

In September 2024, Kamada announced the expansion of its plasma collection operations in Texas with the opening of a new site in Houston.

What was a key product achievement for Kamada in late 2023?

In October 2023, Kamada announced achievements with CYTOGAM®, including the availability of the company-manufactured product for U.S. commercial sale and the presentation of new clinical data.

When did Kamada acquire a plasma collection center?

In February 2021, Kamada acquired an FDA-licensed plasma collection center from Blood and Plasma Research, Inc. in Texas, USA.

What was a notable strategic transaction for Kamada in late 2021?

In November 2021, Kamada announced a strategic transformational transaction, positioning the company as a global leader in the plasma-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved commercial products.